Olfera的动态

“Almac Discovery warmly welcomes today’s launch of the Future Medicines Institute (FMI). We are excited to start the journey on this five-year UKRI project and look forward to developing sector-relevant skills, enhancing access to cutting edge equipment and expertise, driving business opportunity and growth and ultimately to seeing direct benefits to patients in NI and beyond.” Dr Stephen Barr, President and Managing Director of Almac Discovery. Read more: https://hubs.li/Q02-nYyD0

I learned from one of my previous managers (Andy Barlow) that it’s not important how many things you start, but how many things you finish. Now, after years, with the support of our leaders Priv.- Doz. Dr. med. Lukas Martin, MHBA and Georg Griesemann and the team Adrian Alexandru Chiper, Paula Filip, Balan Andrei Mihai, Adrian Manigutiu, Olguta Stanescu, Adrian Mosutiu, Catalin Bobolicu, we focus on getting the things done while looking into the future ??. Thanks ABC Incubator for hosting us! Clinomic Romania II Clinomic

Have you seen the agenda for the Hit ID Summit? See the full event guide via the website here: https://ter.li/ohvqeg Here's a peak at the highlights: ?? - Tailoring the available, different, screening approaches and match them to your specific targets ?? - Taking cross learnings from peers and case study presentations to inform hit strategy ?? - Leveraging DEL, HTS, AI, FBDD, to give a more holistic and detailed picture of how to optimise hit screening With Expert Speakers: Andrew Zhang, Director, Chemical Biology, AstraZeneca Bakhos Tannous, Head, NeuroOncology Discovery, AstraZeneca Christopher Barbieri, Associate Director, Molecular Pharmacology & Screening Technologies, Bristol Myers Squibb Brian Dill, Director, Proteomics, BPGbio, Inc. Yifan Song, Chief Scientific Officer, Cyrus Biotechnology Karenbir Pahil, Investigatior, GSK Spurti Akki, PhD, Senior Scientist, insitro Pat Brady, Senior Director, Computational Chemistry, Kymera Therapeutics Oscar Huang, Associate Director, Biophysics, Lyterian Therapeutics Fabien Vincent, Research Fellow, Pfizer Tim Foley, Lab Head, DNA-Encoded Library, Selection & Pharmacology, Pfizer Woody Sherman, Chief Innovation Officer, Psivant Therapeutics Scott Barraza, Group Leader, Early Discovery Therapeutics, PTC Therapeutics, Inc. Shruthi Bharadwaj, Ph.D, Global Lead, Digital & Analytics, Sanofi Brent Martin, Vice President, Chemical Biology, Scorpion Therapeutics Taosheng Chen, Head of High Throughput Biology, St Jude Children's Hospital Nii Ayi Hesse, Senior Research Scientist, The Francis Crick Institute Rachael Jetson, Senior Director, Lead Discovery, Valo Health Steven Fesik, Professor, Biochemistry, Pharmacology, & Chemistry, Vanderbilt University #hitidentification #hitid #hitscreening #hitfinding #hittolead #drugdiscovery #discovery #undruggable #drugdevelopment #HTS #DEL #dnaencodedlibraries #AI #chemicallibraries

Tomorrow is GACI/ARHR2 Awareness Day – a time to recognize and support the patients and families affected by these rare conditions. At Inozyme Pharma, we are committed to advancing research and deepening our understanding to drive meaningful progress. ? That’s why we’ve partnered with GACI Global to launch the PROPEL Registry – a critical initiative collecting real-world data to improve our knowledge of GACI and ARHR2 and their impact on patients’ lives. ? Watch Christine O'Brien and Liz Molloy from GACI Global discuss the importance of this registry and how our collaboration is shaping the future of research. ? #GACIAwareness #ARHR2 #RareDisease

Are you in the Life Sciences Eco-system and in the GTA? Here is an event to look into!

Next week I’ll be joining the Ori team at #CGMesa24 in Arizona. Two things you should not miss: 1?? Panel Discussion on Mon, 7th at 7:45 AM: Gain insights into pre-clinical development strategies to help safeguard commercial success. ?? 2?? IRO Platform Demo: See our cutting-edge IRO technology in action. Be sure to book your demo slot before they fill up! ?? Please come say hello and let's chat about driving innovation forward, together! #manufacturingbrighterfutures

Good opportunity to learn from SciBite’s Head of Ontologies, Jane Lomax, and J Christian Baber from Pistoia Alliance on the importance and application of #ontologies in the context of #genAI in the #lifesciences.

?????????? ???????? ???????? ?????????? ???? ?? ?????? ?????? ??????????-????-??????-?????? ???????????????????? ???????????????? On July 1st, 2024, the preclinical CRO and MVIC partner, Truly Labs, gained access to new facilities in a brand-new state-of-the-art laboratory building for advanced research and medical development at Medicon Village. The facility has been designed by architects specialising in laboratory environments, and in close dialogue with the tenants. Truly Labs now have sole access to 1200 m2 on the top floor of building 407, containing both laboratories, offices and social space. “This enables continuous company growth and an expansion of our service offer.”, says Karin von Wachenfeldt, CEO at Truly Labs. This will also be beneficial for MVIC customers, who will be offered a wider range of services within the new facilities. In particular, the new labs will allow for further expansion of Truly Labs’ ???? ?????????? services that can prepare projects for efficient and 3R optimized in vivo studies. Truly Labs will still have access to their specialised inhalation laboratories within the animal facility at Medicon Village and will continue to offer ???? ???????? inhalation studies for MVIC customers.

A very interesting read describing some incredible work carried out by the Meek lab (Texas A&M) in collaboration with the Lamb lab (U of Texas, San Antonio) investigating small molecule reversible covalent inhibitors demonstrating dual action to inhibit both SARS-CoV-2 3CL-protease and human cathepsin-L, two cysteine proteases important in COVID-19 infection. Dual inhibitors are considered an effective therapeutic strategy to overcome drug resistance developed by infectious pathogens due to escape mutations etc. The work details designing, synthesizing, and evaluating peptidomimetic aldehyde dual-target inhibitors using two peptide scaffolds based on those of two Pfizer 3CL-PR inhibitors, Nirmatrelvir, and PF-835321. Very grateful to have had the opportunity to contribute to this project by solving a crystal structure of 3CL protease-small molecule complex via the molecular replacement method with Audrey Lamb, Kathy Meneely and Zoe Hoffpauir’s guidance as accomplished structural biologists!

?? Have you considered Australia for your next trial? Here is why Australia is a Top Destination for Medical Device Clinical Studies #Australia presents an attractive and efficient option for MedTech innovators looking to streamline clinical development. Whether you're a start-up or an established player, the benefits of running trials there can give your device a head start on the path to commercialization. Here’s why: ? Fast Regulatory Pathway: The TGA’s Clinical Trial Notification (CTN) scheme allows trials to begin without formal pre-approval, significantly reducing startup timelines. ? Cost-Effective R&D Incentives: Companies can claim up to 43.5% cashback on eligible expenses through Australia’s R&D tax rebate, maximizing budgets. ? Global Data Recognition: Clinical data from Australian trials is accepted by regulators like the FDA and EMA, enabling seamless market progression. ? Diverse Patient Recruitment: Australia’s multicultural population ensures robust, generalizable trial data. ? World-Class Research Infrastructure: With cutting-edge facilities and renowned investigators, Australian trials maintain high scientific standards. You can catch up with Deborah Bell this week at AusBiotech or set up a consultation at a more convenient time to explore how Australia can support your clinical development goals. #MedTech #ClinicalTrials #MedicalDevices #Australia #ClinicalResearch #Innovation